7-OH Safety Profile: What the Research Shows

Published by Official Roxy 7-OH | Updated September 2026

7-hydroxymitragynine has attracted growing scientific attention. Here’s a balanced summary of what current research shows about its safety profile.

What We Know

• 7-OH binds primarily to mu-opioid receptors with high affinity
• It is significantly more potent per mg than mitragynine
• It does not appear to recruit beta-arrestin as strongly as classical opioids (potentially fewer respiratory effects)
• It can be habit-forming with regular use

Known Risks

• Nausea (especially on empty stomach)
• Dizziness at high doses
• Dependence with daily use
• Dangerous interactions with CNS depressants

What We Don’t Know

Long-term safety data is limited. Most research has been conducted in vitro or in animal models. Human clinical trials are still limited. This is why responsible use and medical consultation are essential.

Harm Reduction

Practice the five pillars outlined in our responsible use guide. Always buy from vendors that publish lab results. And never hesitate to take a break when you need one.